The Defender Children’s Health Defense News and Views
Close menu
Close menu

You must be a CHD Insider to save this article Sign Up

Already an Insider? Log in

November 19, 2026 › Health Conditions › Toxic Exposures › Views

Toxic Exposures

Death of 6-Year-Old in Chinese Gene-Editing Trial Prompts Questions About Missed Safety Warnings

A six-year-old girl died in Shanghai after receiving experimental CRISPR-based gene-editing therapy for a rare neurological disorder. Investigators found that researchers failed to properly communicate animal safety warnings, while hospital officials approved treatment despite missing documentation.

medical ethics

A six-year-old girl died in Shanghai after receiving experimental CRISPR-based gene-editing therapy for a rare neurological disorder. Now Chinese authorities have dismissed neuroscientist Zilong Qiu of Shanghai Jiao Tong University School of Medicine and another researcher, barring both from scientific projects for five years.

Investigators found that researchers failed to properly communicate animal safety warnings, while hospital officials approved treatment despite missing documentation.

The child’s family reportedly contributed approximately $860,000 toward developing the therapy. The death, initially undisclosed publicly, raises serious questions about informed consent, research transparency and China’s rapidly expanding biotechnology sector.

What happened? A first-in-human experiment ends in death

The girl, identified under the pseudonym Mei, had Snijders Blok-Campeau syndrome, a rare genetic condition affecting brain development, speech and movement.

Qiu’s team developed an experimental base-editing treatment targeting the CHD3 gene. Modified viruses delivered gene-editing instructions into her spinal fluid, aiming to correct a disease-causing DNA mutation.

Following treatment on March 24, 2025, Mei developed serious complications and died seven days later. Hospital investigators attributed her death to treatment-related thrombotic microangiopathy, a condition damaging small blood vessels and organs.

The experimental intervention offered uncertain benefits for a disorder that was not ordinarily fatal.

Safety warnings ignored: What investigators found

Shanghai authorities announced disciplinary action on Nov. 13, identifying several failures:

  • Animal toxicity: Monkey studies revealed liver damage before treatment.
  • Inadequate disclosure: Researchers failed to communicate those warnings promptly to clinical investigators.
  • Ethics oversight: Xinhua Hospital approved treatment without receiving additional safety materials its ethics committee had requested.
  • Informed consent: The family’s consent documents did not explicitly identify death as a potential risk.

The experiment proceeded under China’s investigator-initiated trial pathway, which permitted hospital-based research without direct national regulatory approval.

A prestigious journal, an undisclosed death

A February Nature publication by Kan Yang and collaborators presented preclinical findings without disclosing Mei’s fatal treatment or the family’s financial contributions.

A July investigation by Science and Retraction Watch exposed the omission. Nature subsequently stated that it had not been informed of the relevant clinical and ethical concerns before publication.

The omission raises questions about research integrity, although it does not independently establish that the published experimental results were fabricated.

TrialSite assessment — Accountability must extend beyond the laboratory

The Daily Express emphasizes the shocking death and scientist’s dismissal. Its dramatic framing is understandable, but the deeper story concerns documented institutional failures, not proof that gene editing itself is inherently unsafe.

The evidence supports serious safety and ethics violations. It does not establish deliberate intent to harm or scientific fraud necessarily.

China strengthened oversight of investigator-initiated trials in May. Whether those reforms provide meaningful protection remains uncertain.

For TrialSite News, the central question is unavoidable: If safety warnings were available, why was a vulnerable child exposed before those risks were properly addressed?

Scientific ambition cannot substitute for informed consent. Nor can institutional prestige excuse preventable failures in patient protection.

Originally published by TrialSite News.

Share Options

Add to Google
Suggest A Correction
Close menu

Republish Article

Please use the HTML above to republish this article. It is pre-formatted to follow our republication guidelines. Among other things, these require that the article not be edited; that the author’s byline is included; and that The Defender is clearly credited as the original source.

Please visit our full guidelines for more information. By republishing this article, you agree to these terms.

Woman drinking coffee looking at phone

Join hundreds of thousands of subscribers who rely on The Defender for their daily dose of critical analysis and accurate, nonpartisan reporting on Big Pharma, Big Food, Big Chemical, Big Energy, and Big Tech and
their impact on children’s health and the environment.

  • This field is for validation purposes and should be left unchanged.